white house glp-1 Strikes Pricing Deal With Lilly, Novo HFA Backs Trump's GLP-1 Medicare

Learn why Artificial sweeteners (sucralose, aspartame, acesulfame-K) Can disrupt gut motility and microbiome, compounding GLP-1s digestive effects

5% for placebo 99% of GI-related adverse events were mild or moderate What This Means for Your Practice: Future treatment options: Oral formulations may improve patient acceptance and adherence Simplified protocols: No injection training or storage requirements Expanded access: Oral options may appeal to injection-averse patients Timeline planning: Orforglipron regulatory submissions beginning this year suggest potential approval in 2026-2027 Action Items: Begin patient education about upcoming oral options

This is particularly the case for women whose achievements were underplayed until very recently

Int J Obes Suppl 6 , S15S21, (2016)

7 , e001112 (2021)

Alimentary Pharmacology & Therapeutics, 2024